The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company ...

Researchers aim to develop a universal vaccine platform that could protect against both COVID-19 and influenza without annual ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development ... are urged to get Covid-19 shots each fall.

Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

Novavax on Thursday tried to calm investors spooked by the delay of full approval of its COVID vaccine shot by U.S.

A novel AI-driven method helps scientists stay ahead of viral evolution by engineering synthetic spike proteins that ...

R&D expenses were $89 million, compared to $93 million a year ago, primarily due to reductions in overall expenditures related to COVID-19 vaccine development. SG&A expenses reached $48 million ...

SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the "Company" or "Vaxart") today announced its business update and financial results for the first quarter of ...

Trump halted biological research funding to adversaries such as China and Iran because of concerns COVID-19 originated in a ...

The World Health Organization’s pandemic agreement represents a powerful commitment to global health and security, writes Nina Schwalbe In April in Geneva, as the US withdrew from engagement in global ...